2020
Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy
Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo W, Richards D, Halperin D, Ge P, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clinical Colorectal Cancer 2020, 19: e117-e123. PMID: 32284253, DOI: 10.1016/j.clcc.2020.03.002.Peer-Reviewed Original ResearchConceptsAbnormal endoscopic findingsAntiangiogenesis cancer therapyIntensive care unitAntiangiogenesis therapyACD symptomsAntimotility agentsEndoscopic findingsColonic perforationCare unitTertiary care cancer centerActive histologic inflammationRare adverse eventsCancer therapyEnterocolitis symptomsHistologic inflammationNonulcerative inflammationUnderlying malignancyGastrointestinal injuryGastrointestinal toxicityMucosal ulcerationUnderwent endoscopyAdverse eventsMedian durationMost patientsEndoscopic evaluationNeutropenic Enterocolitis: Clinical Features and Outcomes.
Abu-Sbeih H, Ali F, Chen E, Mallepally N, Luo W, Lu Y, Foo W, Qiao W, Okhuysen P, Adachi J, Hachem R, Altan M, Jenq R, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Diseases Of The Colon & Rectum 2020, 63: 381-388. PMID: 31842164, DOI: 10.1097/dcr.0000000000001548.Peer-Reviewed Original ResearchConceptsMD Anderson Cancer CenterNeutropenic enterocolitisGranulocyte colony-stimulating factorAnderson Cancer CenterCancer CenterColony-stimulating factorMucosal injuryClinical featuresSurvival rateTexas MD Anderson Cancer CenterConcomitant systemic infectionImmunosuppressive therapy useDuration of neutropeniaRetrospective cohort studyAbsolute neutrophil countCox regression analysisComprehensive cancer centerLower survival rateAbdominal symptomsEnterocolitis diagnosisEnterocolitis symptomsNeutropenia onsetPneumatosis intestinalisCohort studyColonic perforation
2018
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. Journal For ImmunoTherapy Of Cancer 2018, 6: 142. PMID: 30518410, PMCID: PMC6280383, DOI: 10.1186/s40425-018-0461-4.Peer-Reviewed Original ResearchConceptsMean durationImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisImmune checkpoint inhibitor treatmentAbnormal endoscopic findingsActive histologic inflammationCheckpoint inhibitor treatmentClinical success rateRetrospective case seriesGood safety profileFeatures of chronicityMulti-center studyEndoscopic remissionHistologic inflammationHistologic remissionICI therapyNonulcerative inflammationSteroid therapyVedolizumab infusionsVedolizumab therapyClinical remissionMicroscopic colitisMucosal ulcerationSystemic immunosuppressionAdvanced malignanciesImportance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Abu-Sbeih H, Ali F, Luo W, Qiao W, Raju G, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2018, 6: 95. PMID: 30253811, PMCID: PMC6156850, DOI: 10.1186/s40425-018-0411-1.Peer-Reviewed Original ResearchConceptsEndoscopic featuresClinical outcomesHistologic featuresGrade 3Immune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisLogistic regressionActive histologic inflammationActive histological inflammationBackgroundImmune checkpoint inhibitorsExtensive colonic involvementMore frequent hospitalizationsMore recurrent symptomsHigh-risk featuresMultivariate logistic regressionSuch adverse eventsTime of onsetHistologic inflammationICPI treatmentCheckpoint inhibitorsColonic involvementEndoscopic inflammationHistological inflammationMucosal ulcerationRecurrent symptoms